Efficacy and safety of gyejigachulbutang on patient with facet joint syndrome treated by posterior medial branch block - pilot study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0001379

Enrollment

Registered

2015-02-13

Start date

2015-02-23

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Control group : posterior medial branch block once per 2 weeks. two times treatment. Experimental group : 1. posterior medial branch block once per 2 weeks. two times treatment.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Facet joint syndrome patients, shows minimum 50% decrease of pain after posterior medial branch block as diagnotic purpose. 2. Age 20 to 75 years. 3. Ability to comprehend or express oneself in the Korean language 4. Follow-up possible during the clinical trial 5. Written informed consent voluntarily

Exclusion criteria

Exclusion criteria: 1. All contraindications to corticosteroid injection (e.g., insulin-dependent diabetes) 2. Senile dementia, impaired cognitive function or other cerebral disease, severe psychiatric or psychological disorders 3. Alcohol/drug abuse 4. Significant renal or hepatic disease 5. Pregnant, lactating or planning a pregnancy 6. suspected severe heart disease in ECG 7. Refusal to participate in the trial or to provide informed consent 8. An individual deemed to be ineligible by a physician

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale(VAS);Painvision	—

Secondary

Measure	Time frame
Short form McGill pain questionnaire(SF-MPQ);Oswestry Disability Index(ODI)	—

Countries

Korea, Republic of

Contacts

Public ContactHyun-Jong Lee

Daegu Oriental Hospital of Daegu Haany University

whiteyyou@hanmail.net+82-53-770-2115

Outcome results